Search Results
Search this site
658 results found with an empty search
- Orion Pharma and Qilu partner on pembrolizumab biosimilar for Europe
Orion Pharma and Qilu Pharma Europe have entered a European commercialisation agreement for a proposed intravenous pembrolizumab biosimilar. Orion receives exclusive rights to distribute, market and sell the product across Europe, while Qilu will retain responsibility for development and supply. Qilu will receive a share of Orion's profits as well as development, regulatory and sales milestone payments under the agreement. Field Content Article Type Deals Companies Orion Pharma; Qilu Pharma Europe Deal Type Exclusive European commercialisation agreement Key Asset Intravenous pembrolizumab biosimilar Reference Product Keytruda Therapy Area Oncology Technology/Modality Monoclonal antibody biosimilar Geography Europe Commercial Rights Orion receives exclusive rights to distribute, market and sell the biosimilar across Europe Development Responsibilities Qilu Pharma Europe will develop the product Supply Responsibilities Qilu Pharma Europe will supply the product Financial Terms Profit share plus development, regulatory and sales milestone payments; amounts not disclosed What Happened Orion Pharma and Qilu Pharma Europe entered an agreement covering European commercialisation of a proposed intravenous pembrolizumab biosimilar. Why It Matters The agreement gives Orion access to a high-value oncology biosimilar opportunity while providing Qilu with an established European commercial partner. Strategic Rationale Orion contributes European commercial infrastructure while Qilu retains development and manufacturing responsibilities for the biosimilar. Potential Impact The partnership could increase future competition in the European pembrolizumab market if the biosimilar gains regulatory approval. Key Takeaway Orion has secured exclusive European commercial rights to Qilu's proposed pembrolizumab biosimilar. What to Watch Development progress, European regulatory filing and approval, launch timing and disclosure of additional commercial terms. Primary Source Orion Pharma Relevant Date 6 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Italfarmaco licenses JCR's Phase III Hunter syndrome therapy JR-141 across US, Europe and Latin America
Italfarmaco has licensed JCR Pharmaceuticals' Phase III Hunter syndrome therapy JR-141 across the US, Europe and Latin America. Italfarmaco receives exclusive development and commercialisation rights to the blood-brain-barrier-penetrating enzyme replacement therapy, which is already approved in Japan as IZCARGO. JCR will retain manufacturing responsibility and receive upfront, milestone and royalty payments as well as supply revenue under the agreement. Field Content Article Type Deals Companies Italfarmaco; JCR Pharmaceuticals Deal Type Exclusive regional licensing agreement Key Asset JR-141 Approved Brand IZCARGO Indication Hunter syndrome Therapy Area Rare disease; metabolic disease Technology/Modality Blood-brain-barrier-penetrating enzyme replacement therapy Development Stage Global Phase III Licensed Territories United States; Europe; Latin America Existing Approval Approved in Japan as IZCARGO Development Rights Italfarmaco receives exclusive development rights in licensed territories Commercial Rights Italfarmaco receives exclusive commercialisation rights in licensed territories Manufacturing Responsibility JCR Pharmaceuticals retains manufacturing responsibility Financial Terms Upfront, milestone and royalty payments plus supply revenue; amounts not disclosed What Happened Italfarmaco licensed JR-141 from JCR Pharmaceuticals for development and commercialisation across the US, Europe and Latin America. Why It Matters The agreement gives Italfarmaco access to a late-stage rare-disease therapy designed to cross the blood-brain barrier, addressing both systemic and neurological manifestations of Hunter syndrome. Supporting Context JR-141 is already marketed in Japan as IZCARGO and is progressing through global Phase III development. Strategic Rationale Italfarmaco gains a differentiated late-stage rare-disease asset while JCR expands JR-141's international reach through a regional commercial partner. Potential Impact If approved, JR-141 could broaden treatment options for Hunter syndrome patients across major Western and Latin American markets. Key Takeaway Italfarmaco has secured rights to Phase III Hunter syndrome therapy JR-141 across the US, Europe and Latin America. What to Watch Phase III results, regulatory submissions in licensed markets and timing of potential launches outside Japan. Primary Source JCR Pharmaceuticals Relevant Date 2 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Alvotech and LOTTE Biologics sign US manufacturing partnership for multiple biosimilars
Alvotech and LOTTE Biologics have entered a US manufacturing agreement covering multiple antibody biosimilars for global supply. LOTTE Biologics will manufacture drug substance at its 40,000-litre facility in Syracuse, New York, expanding Alvotech's production capacity and geographic manufacturing footprint. The companies have also left scope to broaden the collaboration over time as Alvotech advances additional biosimilar programmes. Field Content Article Type Deals Companies Alvotech; LOTTE Biologics Deal Type Long-term manufacturing partnership Programme Scope Multiple antibody biosimilars Technology/Modality Monoclonal antibody biosimilars Manufacturing Site Syracuse, New York, United States Manufacturing Capacity 40,000 litres Supply Scope Global supply Manufacturing Responsibility LOTTE Biologics will manufacture drug substance for selected Alvotech biosimilars What Happened Alvotech and LOTTE Biologics signed a US-based manufacturing agreement covering multiple antibody biosimilars. Why It Matters The agreement adds manufacturing capacity and geographic diversification to Alvotech's global biosimilar supply network. Strategic Rationale Alvotech can broaden and de-risk production while LOTTE Biologics increases utilisation of its large-scale US biologics manufacturing infrastructure. Potential Impact Additional US manufacturing capacity could support global supply resilience as Alvotech's biosimilar portfolio expands. Key Takeaway LOTTE Biologics will manufacture multiple Alvotech antibody biosimilars at its 40,000-litre Syracuse facility. What to Watch Identification of the covered biosimilars, timing of technology transfer and potential expansion of the partnership to additional programmes. Primary Source Alvotech Relevant Date 6 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- UK government accepts all 44 recommendations for new healthcare AI regulatory framework
The UK government has accepted all 44 recommendations from the National Commission into the Regulation of AI in Healthcare, moving its proposed framework into implementation. The new approach is intended to make healthcare AI regulation more proportionate, risk-based and lifecycle-focused, with clearer accountability and continuous real-world monitoring. The MHRA has also opened Phase 3 of its AI Airlock regulatory sandbox, creating a practical route for testing how the recommendations could operate in real-world regulatory settings. Field Content Article Type Industry Updates Organisation UK Government; MHRA Policy Area Healthcare AI regulation Development Government acceptance of all 44 recommendations from the National Commission into the Regulation of AI in Healthcare Geography United Kingdom Regulatory Approach Proportionate, risk-based and lifecycle-focused regulation Key Measures Continuous real-world monitoring; clearer accountability; transparency; proportionate oversight Implementation Mechanism MHRA AI Airlock Phase 3 regulatory sandbox What Happened The UK government accepted all 44 recommendations from the National Commission into the Regulation of AI in Healthcare. Why It Matters The decision moves the Commission's proposals from recommendation into government-backed implementation and signals a more formal regulatory framework for healthcare AI. Supporting Context The recommendations call for lifecycle regulation, clearer allocation of responsibility and continued monitoring of AI technologies after deployment. Potential Impact Developers and healthcare organisations may face clearer expectations around evidence, accountability, safety monitoring and transparency across the full lifecycle of AI-enabled technologies. Key Takeaway The UK government has backed all 44 healthcare AI regulatory recommendations and begun implementation through the MHRA's AI Airlock programme. What to Watch Detailed regulatory guidance, MHRA implementation timelines, outcomes from AI Airlock Phase 3 and any legislative changes required to embed the framework. Primary Source UK Government Relevant Date 6 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- CSL and Alentis sign lixudebart partnership worth up to $1.555bn plus profit share
CSL and Alentis Therapeutics have entered a global lixudebart partnership worth up to $1.555 billion, with future profits shared between the companies. CSL will pay $355 million initially and up to $1.2 billion in commercial milestones for the Phase II claudin-1 monoclonal antibody targeting rare kidney and liver diseases. CSL will fund specified Phase II and Phase III development, while global profits will be split 55% to CSL and 45% to Alentis. Field Content Article Type Deals Companies CSL; Alentis Therapeutics Deal Type Global co-development and co-commercialisation partnership Key Asset Lixudebart Therapy Areas Rare kidney disease; rare liver disease Technology/Modality Claudin-1 monoclonal antibody Development Stage Phase II Initial Payment $355 million Potential Commercial Milestones Up to $1.2 billion Potential Deal Value Up to $1.555 billion Development Funding CSL will fully fund specified Phase II and Phase III development Profit Share 55% CSL; 45% Alentis What Happened CSL and Alentis entered a global partnership to develop and commercialise lixudebart. Why It Matters The agreement gives CSL access to a clinical-stage rare-disease programme while providing Alentis with substantial funding and a retained share of future economics. Supporting Context Lixudebart targets claudin-1 and is being developed for serious rare kidney and liver diseases. Strategic Rationale CSL is expanding its rare-disease pipeline while Alentis gains a global development and commercial partner for a lead clinical asset. Potential Impact Successful development could create a new treatment approach for rare fibrotic kidney and liver conditions with limited therapeutic options. Key Takeaway CSL and Alentis have partnered on lixudebart in a deal worth up to $1.555 billion plus a 55:45 profit share. What to Watch Phase II results, transition into Phase III development and future regulatory strategy. Primary Source CSL Relevant Date 5 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- FDA approves new CardioMEMS patient-facing capabilities for remote heart failure management
The FDA has approved new patient-facing CardioMEMS HF System capabilities that allow people with heart failure to view pulmonary artery pressure readings and receive personalised treatment updates. The CardioGuide HF App can now display pulmonary artery pressure data directly to patients, while Dynamic Treatment Plan functionality enables care teams to communicate personalised medication guidance. The upgrade expands CardioMEMS from a clinician-focused remote monitoring platform into a more interactive tool supporting patient participation in heart-failure management. Field Content Article Type Approvals Product CardioMEMS HF System Company Abbott Regulatory Authority U.S. Food and Drug Administration Approval Type Product capability expansion Indication Remote management of heart failure Therapy Area Cardiology; heart failure Technology/Modality Implantable pulmonary artery pressure monitoring system with patient-facing digital health capabilities Patient App CardioGuide HF App New Capability Patients can view pulmonary artery pressure readings directly Treatment Feature Dynamic Treatment Plan functionality for personalised medication updates from care teams Geography United States What Happened The FDA approved new patient-facing capabilities for Abbott's CardioMEMS HF System. Why It Matters The approval gives patients direct access to haemodynamic information and treatment guidance that previously centred primarily on clinician monitoring. Supporting Context CardioMEMS remotely measures pulmonary artery pressure to help identify worsening heart failure before symptoms become severe. Potential Impact Greater patient visibility and personalised treatment communication may support earlier intervention and stronger engagement in chronic heart-failure care. Key Takeaway FDA-approved CardioMEMS updates allow patients to see pressure readings and receive personalised treatment instructions through Abbott's app. What to Watch US rollout, patient uptake, clinician adoption and evidence on whether the new capabilities improve adherence or heart-failure outcomes. Primary Source Abbott Relevant Date 5 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- GE HealthCare agrees $945m acquisition of SOFIE Biosciences to expand US radiopharma network
GE HealthCare has agreed to acquire SOFIE Biosciences for $945 million, expanding its US PET radiopharmaceutical manufacturing and distribution network. The acquisition adds SOFIE's US radiopharmaceutical infrastructure and rights to the Phase III FAPI-74 pan-cancer imaging radiotracer. The deal strengthens GE HealthCare's final-mile PET supply capabilities and broadens its position in precision imaging and radiopharmaceuticals. Field Content Article Type Deals Companies GE HealthCare; SOFIE Biosciences Deal Type Acquisition Transaction Value $945 million in cash Acquired Company SOFIE Biosciences Therapy Areas Oncology; diagnostic imaging; nuclear medicine Technology/Modality PET radiopharmaceuticals Key Asset FAPI-74 Development Stage Phase III Infrastructure US PET radiopharmaceutical contract manufacturing and distribution network What Happened GE HealthCare agreed to acquire SOFIE Biosciences for $945 million in cash. Why It Matters The acquisition gives GE HealthCare additional radiopharmaceutical manufacturing and distribution infrastructure in the US while adding a late-stage pan-cancer imaging asset. Supporting Context SOFIE's network supports the final-mile supply of short-lived PET radiopharmaceuticals, an important operational requirement for nuclear medicine imaging. Strategic Rationale GE HealthCare is strengthening its radiopharmaceutical platform and expanding its ability to manufacture and distribute F18 PET products closer to imaging centres. Potential Impact The transaction could broaden access to PET imaging agents and strengthen GE HealthCare's position in precision oncology imaging. Key Takeaway GE HealthCare is acquiring SOFIE Biosciences for $945 million to expand its US radiopharmaceutical network and add FAPI-74. What to Watch Transaction completion, integration of SOFIE's network and Phase III development and potential commercialisation of FAPI-74. Primary Source GE HealthCare Relevant Date 5 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Genentech licenses Alector brain-penetrant Parkinson's programme in deal worth up to $1.27bn
Genentech has licensed Alector's brain-penetrant AL050 programme in a neurodegeneration deal worth up to $1.27 billion. Alector will receive $100 million upfront and could earn up to $1.17 billion in development, regulatory and commercial milestones, plus tiered royalties. AL050 is a preclinical GCase enzyme replacement therapy using Alector's Brain Carrier platform to cross the blood-brain barrier and is being developed for Parkinson's disease. Field Content Article Type Deals Companies Genentech; Alector Deal Type Exclusive global licensing agreement Key Asset AL050 Therapy Area Parkinson's disease; neurodegeneration Technology/Modality Brain-penetrant GCase enzyme replacement therapy Platform Alector Brain Carrier Development Stage Preclinical Upfront Payment $100 million Potential Milestones Up to $1.17 billion Potential Deal Value Up to $1.27 billion Additional Economics Tiered royalties Geography Worldwide What Happened Genentech secured exclusive worldwide rights to Alector's AL050 programme. Why It Matters The transaction gives Genentech access to a blood-brain-barrier delivery platform designed to enable enzyme replacement therapy in neurodegenerative disease. Supporting Context AL050 is designed to deliver GCase into the brain using Alector's Brain Carrier technology. Strategic Rationale Genentech is expanding its neurodegeneration pipeline with a differentiated approach to brain delivery, while Alector monetises a preclinical programme and platform capability. Potential Impact If successful, AL050 could support a new disease-modifying treatment approach in Parkinson's disease. Key Takeaway Genentech has licensed AL050 from Alector in a deal worth up to $1.27 billion. What to Watch IND-enabling work, entry into clinical development and early evidence of brain penetration and GCase activity. Primary Source Alector Relevant Date 5 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- FDA expands Jaypirca approval to first-line treatment of CLL and SLL
The FDA has moved Jaypirca into first-line CLL and SLL treatment following Phase III data showing a substantial reduction in the risk of disease progression or death. Jaypirca (pirtobrutinib) is now approved for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion. In BRUIN CLL-313, median progression-free survival was not reached with Jaypirca compared with 33.5 months for bendamustine plus rituximab, corresponding to a hazard ratio of 0.20. Field Content Article Type Approvals Drug Name Pirtobrutinib Brand Name Jaypirca Company Eli Lilly and Company Regulatory Authority U.S. Food and Drug Administration Approval Type Indication expansion to first-line treatment Indication Previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion Patient Population Adults Therapy Areas Oncology; haematology Technology/Modality Non-covalent BTK inhibitor Clinical Study Phase III BRUIN CLL-313 Key Result Median progression-free survival was not reached with Jaypirca versus 33.5 months with bendamustine plus rituximab; hazard ratio 0.20 Geography United States What Happened The FDA expanded Jaypirca's indication to include first-line treatment of eligible adults with previously untreated CLL or SLL. Why It Matters The decision moves the first and only approved non-covalent BTK inhibitor into an earlier treatment setting for CLL and SLL. Supporting Context The approval was supported by Phase III BRUIN CLL-313 data demonstrating a substantial reduction in the risk of progression or death versus bendamustine plus rituximab. Potential Impact The expanded label gives clinicians another targeted first-line treatment option for eligible patients with CLL or SLL. Key Takeaway Jaypirca is now FDA approved for certain previously untreated CLL and SLL patients. What to Watch First-line uptake, treatment sequencing with covalent BTK inhibitors and longer-term survival data. Primary Source U.S. Food and Drug Administration Relevant Date 2 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Shionogi agrees $2bn acquisition of IntraBio to expand rare disease portfolio
Shionogi has agreed to acquire IntraBio for $2 billion, adding the rare neurological disease therapy AQNEURSA and its global commercial rights to the Japanese group's portfolio. The acquisition gives Shionogi ownership of IntraBio and AQNEURSA (levacetylleucine), which is approved for rare neurological disorders including Niemann-Pick disease type C and ataxia associated with ataxia-telangiectasia. The transaction is expected to close in November or December 2026, subject to customary regulatory conditions, and materially expands Shionogi's presence in rare neurological diseases. Field Content Article Type Deals Companies Shionogi; IntraBio Deal Type Acquisition Acquired Company IntraBio Transaction Value $2 billion upfront Key Asset AQNEURSA (levacetylleucine) Therapy Areas Rare disease; neurology Technology/Modality Small-molecule therapy Transaction Scope 100% acquisition of IntraBio, including global intellectual-property and commercial rights to AQNEURSA Expected Closing November-December 2026 What Happened Shionogi agreed to acquire 100% of IntraBio for $2 billion upfront. Why It Matters The acquisition adds an established rare-neurology commercial asset and specialist rare-disease capabilities to Shionogi's portfolio. Supporting Context AQNEURSA is approved in the US and EU for neurological manifestations of Niemann-Pick disease type C and has also received FDA approval for ataxia in patients with ataxia-telangiectasia. Strategic Rationale Shionogi is strengthening its rare-disease and neurological portfolio through ownership of IntraBio's products, intellectual property and commercial capabilities. Potential Impact The transaction could accelerate Shionogi's expansion in rare neurological diseases while supporting broader commercial development of AQNEURSA. Key Takeaway Shionogi is acquiring IntraBio for $2 billion to add AQNEURSA and expand its rare-disease business. What to Watch Transaction closing, integration of IntraBio and future geographic or indication expansion for AQNEURSA. Primary Source Shionogi Relevant Date 5 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Saudi regulator approves Jascayd for idiopathic pulmonary fibrosis
Saudi Arabia has approved Jascayd for adults with idiopathic pulmonary fibrosis following Phase III evidence showing reduced decline in lung function. Jascayd (nerandomilast), a preferential PDE4B inhibitor, has been registered by the Saudi Food and Drug Authority for the treatment of adults with idiopathic pulmonary fibrosis. The approval is supported by the 1,177-patient Phase III FIBRONEER-IPF trial, in which treatment produced statistically significant reductions in forced vital capacity decline compared with placebo. Field Content Article Type Approvals Drug Name Nerandomilast Brand Name Jascayd Regulatory Authority Saudi Food and Drug Authority Approval Type Marketing approval Indication Idiopathic pulmonary fibrosis Patient Population Adults Therapy Areas Pulmonology; respiratory disease Technology/Modality Preferential PDE4B inhibitor Clinical Study Phase III FIBRONEER-IPF Study Population 1,177 patients Key Result Jascayd demonstrated statistically significant reductions in decline of forced vital capacity versus placebo. Geography Saudi Arabia What Happened The Saudi Food and Drug Authority approved Jascayd for adults with idiopathic pulmonary fibrosis. Why It Matters The approval introduces another treatment option for a progressive fibrotic lung disease associated with declining respiratory function. Supporting Context The regulatory decision was supported by the Phase III FIBRONEER-IPF programme involving 1,177 patients. Potential Impact Jascayd could broaden treatment choice for adults with IPF in Saudi Arabia and support wider regional uptake of the therapy. Key Takeaway Jascayd has received Saudi marketing approval for adult idiopathic pulmonary fibrosis. What to Watch Commercial launch, reimbursement and positioning alongside established antifibrotic therapies. Primary Source Saudi Food and Drug Authority Relevant Date 3 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- South Korean doctors earn ₩285.18 million a year, latest government data show
South Korea has published its latest official healthcare workforce survey, providing a new government benchmark for physician remuneration and working conditions across the country's healthcare system. Full-time physicians working in South Korean healthcare institutions earned average annual remuneration of ₩285.18 million, according to the latest official physician compensation data published by the Ministry of Health and Welfare. South Korea's latest government data provide a new benchmark for physician compensation, revealing substantial differences in average remuneration according to the type of healthcare institution in which doctors work. Full-time physicians working in healthcare institutions received average annual remuneration of ₩285.18 million, equivalent to approximately ₩23.77 million per month when divided across 12 months. The figures come from the Ministry of Health and Welfare's Second Healthcare Workforce Conditions Survey, published on 29 September 2026. The underlying remuneration data relate to 2023, making them the latest official government figures rather than a measure of earnings during 2026. Key findings Average annual physician remuneration: ₩285.18 million Approximate monthly equivalent: ₩23.77 million Hospitals: ₩354.27 million Clinics: ₩325.99 million General hospitals: ₩251.45 million Tertiary general hospitals: ₩199.76 million Doctors working at least 40 hours per week were included Interns and residents were excluded Remuneration was based on salary information used for National Health Insurance contributions The remuneration figures relate to 2023, with the official survey results published in September 2026 Average physician remuneration reaches ₩285.18 million The Ministry reports average annual remuneration of ₩285.18 million among physicians working full-time in healthcare institutions. That equates to approximately ₩23.77 million per month, although the Ministry's measure is annual remuneration rather than a monthly salary benchmark. The survey includes doctors working at least 40 hours per week while excluding interns and residents, providing a benchmark focused on the established physician workforce. Unlike compensation surveys based on doctors voluntarily reporting their earnings, the Ministry's remuneration measure uses the monthly remuneration base employed in calculating National Health Insurance contributions. It should therefore be understood as recorded employment remuneration rather than a measure of every potential source of professional income available to a physician. Physician remuneration varies substantially by institution One of the most notable findings is the difference in physician remuneration between different types of healthcare institutions. Physicians working in hospitals recorded the highest average annual remuneration at ₩354.27 million. This was followed by: Clinics: ₩325.99 million General hospitals: ₩251.45 million Tertiary general hospitals: ₩199.76 million The difference between the highest and lowest institutional averages was substantial. Average physician remuneration in hospitals was approximately ₩154.51 million higher than in tertiary general hospitals. On this measure, the hospital average was approximately 77% higher than the tertiary-general-hospital average. Why do institution-level differences matter? The figures demonstrate why a single national average cannot describe the compensation of every South Korean physician. The type of healthcare institution in which a doctor works is associated with substantially different average remuneration levels in the Ministry's data. However, the figures should not be interpreted as demonstrating that the institution type itself causes the difference. Factors such as physician characteristics, working arrangements, specialty mix, seniority and the structure of medical activity within different types of healthcare organisations may contribute to the variation. The institution-level figures are therefore most useful as national compensation benchmarks rather than expected salaries for individual doctors. What does the latest figure mean for South Korean physicians? The ₩285.18 million annual average provides a new official benchmark for assessing physician remuneration in South Korea. The underlying methodology also makes the findings particularly valuable for compensation research. Rather than relying on advertised salaries or self-reported estimates, the remuneration measure is based on salary information used to calculate National Health Insurance contributions. There are nevertheless important limitations. The figures do not provide individual specialty benchmarks for areas such as cardiology, oncology or dermatology, and they should not be interpreted as capturing every possible source of physician professional income. They also represent average rather than median remuneration, meaning the figures do not indicate what the physician at the midpoint of the earnings distribution received. Latest release, but 2023 remuneration The timing of the data is important when interpreting the findings. The Ministry published its Second Healthcare Workforce Conditions Survey on 29 September 2026, but the physician remuneration figures relate to 2023. The figures should therefore not be described as what South Korean physicians "earn in 2026". Instead, they represent the latest official physician remuneration data available from the South Korean government as of 2026. This distinction is particularly important when comparing physician compensation internationally, as official healthcare workforce datasets are often released considerably later than the period to which the earnings data relate. About the data South Korea's Ministry of Health and Welfare published the Second Healthcare Workforce Conditions Survey on 29 September 2026. For physician remuneration, the survey uses the monthly remuneration base applied to National Health Insurance contributions. The reported figures cover doctors working at least 40 hours per week in healthcare institutions and exclude interns and residents. The remuneration figures relate to 2023. Source Ministry of Health and Welfare, Republic of Korea. Second Healthcare Workforce Conditions Survey. Published 29 September 2026.https://www.mohw.go.kr/board.es?mid=a10503010100&bid=0027&tag=&act=view&list_no=1492074&cg_code= Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com



